^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Krabeva (bevacizumab biosimilar)

    i
    Other names: MYL-1402O, Bmab-100, Bmab100
    Company:
    Biocon, Sandoz
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    4years
    MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC (clinicaltrials.gov)
    P3, N=671, Completed, Mylan Inc.
    Clinical • New P3 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4)
    |
    ALK rearrangement
    |
    paclitaxel • Krabeva (bevacizumab biosimilar)
    5years
    Identification of a specific epigenetic signature in patients showing secondary hypertension upon anti-VEGF treatment from the GEICAM/2011-04 (BRECOL) study (SABCS 2019)
    METHODS Patients (n=113) from BRECOL study (NCT01733628) received bevacizumab in combination with oxaliplatin or irinotecan + fluoropyrimidines for metastatic colorectal cancer (n=49), and with paclitaxel or capecitabine for metastatic breast cancer (n=64). CONCLUSIONS High BP upon anti-angiogenic treatment is associated to specific DNA methylation profiles. We identified an epigenetic methylation signature putative predictive of secondary HTN to bevacizumab treatment in metastatic breast and colorectal cancer.
    Clinical
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit)
    |
    Avastin (bevacizumab) • paclitaxel • capecitabine • oxaliplatin • irinotecan • Krabeva (bevacizumab biosimilar)